Determining The "ROI" Of Clinical Trial Rescue Before It's Too Late

Have you ever put off broaching a difficult conversation, for fear that the other party might react badly? When the conversation involves a faltering clinical trial, the urge to avoid conflict becomes stronger still. But the longer that difficult conversation is avoided, the greater the risk that the trial progresses from faltering to failing. And the deeper a trial's problems, the greater the potential for significant budget increases — another difficult conversation.

Research shows that more than 30% of Phase II trials, and 58% of Phase III studies, are at risk of failure.¹ Some of that risk is attributable to our natural inclination to avoid the problem; not undertaking corrective action or simply not communicating that a trial is in jeopardy.